FERIDEX I.V.
LOE Approachingferumoxides
NDAINJECTIONINJECTABLE
Approved
Aug 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FERIDEX I.V. (ferumoxides) is clinical pharmacology general: feridex i. First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FERIDEX I.V. (ferumoxides) is an intravenously administered colloidal superparamagnetic iron oxide contrast agent used to enhance MRI imaging of liver lesions. It works by being taken up by cells of the reticuloendothelial system (RES), shortening relaxation times and reducing signal intensity in normal tissue while preserving signal in abnormal tissues (metastases, primary liver cancer, cysts, benign tumors), thereby increasing contrast between healthy and diseased tissue. The iron component enters normal body iron metabolism after imaging.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job openings; team likely focused on defending market share against emerging alternatives.
Mechanism of Action
CLINICAL PHARMACOLOGY General: Feridex I.V. is an intravenously injected colloidal superparamagnetic iron oxide associated with dextran. It is a magnetic resonance imaging (MRI) contrast agent and is taken up by cells of the reticuloendothelial system (RES). Pharmacokinetics: Three healthy, adult…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.